If you are interested in the field of oncology, you may have heard of Jean-Pierre Armand, a French doctor who has made significant contributions to cancer research and treatment. He is the founder and president of the scientific board of the European Precision Medicine Institute (PreciMed), a co-founder of PEGASCY, a biotech company that repurposes drugs discarded by big pharmas, and a senior consultant at Institut Gustave Roussy, one of the leading cancer centers in Europe.

In this article, we will explore his background, achievements, and current projects, and learn why he is considered one of the most influential oncologists in the world.

Jean-Pierre Armand was born on August 6, 1950 in France. He obtained his medical degree from the University of Toulouse III and his certification in medical oncology from the University of Paris XI. He also holds a master’s degree in science.

He started his career as a head of early clinical new drugs programs and medical director of research and development at Institut Gustave Roussy in Villejuif, where he was involved in phase I, II, and III studies for the treatment of solid tumors.

Jean-Pierre Armand has been an active member of the medical oncology community for decades. He has held various leadership positions in prestigious organizations, such as:

• President of the European Society for Medical Oncology (ESMO)
• Medical Director of the Federation of European Cancer Societies (FECS)
• President of the French Cancer Society (SFC)
• Chairman of the protocol review committee at the European Organization for Research and Treatment of Cancer (EORTC)
• Chairman of oncology of the French branch of EMEA (now EMA) in Paris
• Member of international boards of the American Association for Cancer Research (AACR)
• Member of scientific committee of the American Society of Clinical Oncology (ASCO) and AACR
• Member of board clinical trials at Institut National du Cancer (INCa)

He has also received several awards for his work, such as:

• The ESMO Award as “the European oncologist of the year” in 2008
• The TAT Award for new drugs in phase I in oncology in 2012

He has published more than 300 papers in peer-reviewed journals and contributed to several books on oncology.

Jean-Pierre Armand is currently working on several projects that aim to advance precision medicine and drug development for cancer patients. He is the founder and president of the scientific board of PreciMed, an institute that brings together experts from different disciplines to collaborate on innovative solutions for cancer diagnosis, prognosis, prevention, and treatment. He is also the co-founder and CEO of PEGASCY, a biotech company that repurposes drugs discarded by big pharmas in phase I trials for new indications in oncology.

In addition, he is a senior consultant at Institut Gustave Roussy, where he established the DITEP new drug research and development system. He is also a visiting professor of oncology at Yunnan University in China.

Jean-Pierre Armand’s vision is to improve the quality of life and survival of cancer patients by developing personalized therapies based on molecular profiling and biomarkers. He believes that precision medicine is the future of oncology and that collaboration among different stakeholders is essential to achieve this goal.

Jean-Pierre Armand is a renowned oncologist and drug developer who has dedicated his life to cancer research and treatment. He has made significant contributions to the field through his leadership roles, publications, awards, and projects. He is currently working on advancing precision medicine and drug repurposing for cancer patients through his involvement in PreciMed, PEGASCY, Institut Gustave Roussy, and Yunnan University.

If